trending Market Intelligence /marketintelligence/en/news-insights/trending/qNszSzT6y7VcflslsJbeMw2 content esgSubNav
In This List

60° Pharmaceuticals seeks US FDA approval for preventive malaria medication

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


60° Pharmaceuticals seeks US FDA approval for preventive malaria medication

60° Pharmaceuticals LLC is seeking approval from the U.S. Food and Drug Administration for Tafenoquine for the prevention of malaria in adults.

The company entered into a cooperative research and development agreement with the U.S. Army Medical Materiel Development Activity in 2014 for the development of the drug.

Tafenoquine has been studied in more than 30 clinical trials involving more than 4,000 participants.